DOCSLIB.ORG

Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies Timothy M

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies Timothy M Published OnlineFirst May 26, 2016; DOI: 10.1158/0008-5472.CAN-16-0058 Cancer Therapeutics, Targets, and Chemical Biology Research Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies Timothy M. Shaver1,2, Brian D. Lehmann1,2, J. Scott Beeler1,2, Chung-I Li3, Zhu Li1,2, Hailing Jin1,2, Thomas P. Stricker4, Yu Shyr5,6, and Jennifer A. Pietenpol1,2 Abstract Triple-negative breast cancer (TNBC) and other molecularly discovered a clinical occurrence and cell line model of the target- heterogeneous malignancies present a significant clinical chal- able FGFR3–TACC3 fusion in TNBC. Expanding our analysis to lenge due to a lack of high-frequency "driver" alterations amena- other malignancies, we identified a diverse array of novel and ble to therapeutic intervention. These cancers often exhibit geno- known hybrid transcripts, including rearrangements between mic instability, resulting in chromosomal rearrangements that noncoding regions and clinically relevant genes such as ALK, affect the structure and expression of protein-coding genes. How- CSF1R, and CD274/PD-L1. The over 1,000 genetic alterations ever, identification of these rearrangements remains technically we identified highlight the importance of considering noncod- challenging. Using a newly developed approach that quantita- ing gene rearrangement partners, and the targetable gene tively predicts gene rearrangements in tumor-derived genetic fusions identified in TNBC demonstrate the need to advance material, we identified and characterized a novel oncogenic fusion gene fusion detection for molecularly heterogeneous cancers. involving the MER proto-oncogene tyrosine kinase (MERTK) and Cancer Res; 76(16); 1–11. Ó2016 AACR. Introduction quency and widely varying clonality of therapeutically action- able alterations across subtypes, including mutations in Despite advances in precision medicine, the treatment of PIK3CA and BRAF,amplification of EGFR,lossofPTEN,and many molecularly heterogeneous cancers remains challenging expression of androgen receptor (AR;refs.3–5). However, a due to a lack of recurrent alterations amenable to therapeutic significant proportion of TNBC cases lack somatic alterations of intervention. To make significant clinical advances against any established "driver" gene, highlighting the importance of these recalcitrant cancers, integrative genomic and molecular continued genomic analysis and discovery integrated with analyses are required to understand their complexity and to molecular profiling of the tumor microenvironment (3). identify targetable features arising from lower-frequency genet- Adefining feature of TNBC and other clinically challenging, ic events. Our laboratory has identified six molecular subtypes molecularly heterogeneous cancers such as ovarian carcinoma of one such heterogeneous disease, triple-negative breast cancer and lung squamous cell carcinoma is copy number alteration (TNBC), with each subtype displaying unique ontologies and (CNA), which is frequently accompanied by mutation or inac- differential response to standard-of-care chemotherapy (1, 2). tivation of the p53 tumor suppressor (4, 6–8). The genomic Ongoing genomic analysis of TNBC has identified a low fre- instability that gives rise to CNA can also result in chromo- somal rearrangements and gene fusions, which have long been 1Department of Biochemistry,Vanderbilt University, Nashville,Tennes- recognized as oncogenic drivers and effective drug targets in a see. 2Vanderbilt-Ingram Cancer Center,Vanderbilt University Medical variety of hematological and solid malignancies (9). In recent Center, Nashville, Tennessee. 3Department of Statistics, National 4 years, the advent of next-generation sequencing (NGS) has Cheng Kung University, Tainan, Taiwan. Department of Pathology, fi Microbiology, and Immunology,Vanderbilt University Medical Center, enabled the identi cation of a number of gene fusion events Nashville, Tennessee. 5Center for Quantitative Sciences, Vanderbilt in epithelial cancers, with varying frequency and therapeutic 6 University Medical Center, Nashville, Tennessee. Department of Bio- relevance (10–14). statistics, Vanderbilt University Medical Center, Nashville, Tennessee. In order to broaden our understanding of the somatic altera- Note: Supplementary data for this article are available at Cancer Research tions underlying TNBC, we sought to identify known and novel Online (http://cancerres.aacrjournals.org/). gene rearrangements affecting the structure and/or expression T.M. Shaver and B.D. Lehmann contributed equally to this article. level of protein-coding transcripts. While a number of compu- Corresponding Authors: Jennifer A. Pietenpol, Vanderbilt-Ingram Cancer tational approaches have been developed to identify hybrid Center, 652 Preston Research Building, 2200 Pierce Avenue, Nashville, RNA and DNA sequences using NGS data, numerous technical TN 37232-6838. Phone: 615-936-1512; Fax: 615-936-1790; E-mail: hurdles complicate accurate and efficient gene rearrangement [email protected]; and Brian D. Lehmann, detection (15). For instance, widespread regions of sequence [email protected] homology and current limitations in read length result in doi: 10.1158/0008-5472.CAN-16-0058 sometimes-ambiguous alignment and a large number of false Ó2016 American Association for Cancer Research. positives. To combat this, many detection methodologies use www.aacrjournals.org OF1 Downloaded from cancerres.aacrjournals.org on September 26, 2021. © 2016 American Association for Cancer Research. Published OnlineFirst May 26, 2016; DOI: 10.1158/0008-5472.CAN-16-0058 Shaver et al. filters designed to enrich for biologically relevant gene rearran- Ba/F3 IL3 withdrawal gements, such as restricting both potential fusion partners to Stably transfected Ba/F3 cells were seeded in 6-well plates protein-coding loci (16). While these filters enrich for currently (40,000 cells/well) in growth medium Æ 1 ng/mL IL3. Live-cell known gene fusions, they are not effective for the discovery of counts were manually determined at three sequential 24-hour less canonical events, such as rearrangements between coding timepoints by visual inspection using a hemocytometer and and noncoding regions of the genome. We developed a new Trypan blue (Bio-Rad). algorithm, Segmental Transcript Analysis (STA), which uses exon-level expression estimates to rank a population of sam- Cloning and generation of stable cell lines ples based on their likelihood of harboring a rearrangement in The TMEM87B-MERTK expression construct, corresponding a given gene. We identified a number of known and novel to amino acids 1-55 of TMEM87B (NM_032824) and amino rearrangements involving functionally diverse gene partners in acids 433-1000 of MERTK (NM_006343), was synthesized in a TNBC, and expanded our analysis and discovery to a wider, pMK-RQ-Bb vector using GeneOptimizer and GeneArt (Life multicancer cohort from The Cancer Genome Atlas (TCGA). Technologies) and cloned into pBABE-puro (19) (Addgene) The DNA-validated rearrangements that we identified include by EcoRI/SalI restriction digest and ligation (New England noncoding portions of the genome acting as both 50 and 30 BioLabs). The complete pBABE-puro-TMEM87B-MERTK ex- partners in clinically relevant hybrid transcripts. pression construct sequence is available upon request. To generate stably transfected cell lines, pBABE-puro-TMEM87B- Materials and Methods MERTK or pBABE-puro empty vector retroviruses were pack- aged in Phoenix cells (Orbigen) and Ba/F3 and MCF10A Cell culture cells were transduced with virus for two 24-hour intervals with SUM185PE (Asterand, March 2010) and MCF10A cells (ATCC, 8 mg/mL polybrene (Sigma), then selected and maintained June 2012) were cultured as previously described (1). Ba/F3 cells with 1.5 mg/mL (Ba/F3) or 0.5 mg/mL (MCF10A) puromycin (provided by Dr. Christine Lovly, Vanderbilt University, Novem- (Sigma). ber 2014) were cultured in RPMI þ GlutaMAX (Gibco 61870) with 1 ng/mL IL3 (Life Technologies) and 5% (v/v) FBS (Gemini). All cell lines were maintained in 100 U/mL peni- Immunoblotting cillin and 100 mg/mL streptomycin (Gemini) and tested neg- SUM185PE cells were lysed 72 hours after siRNA transfection. ative for mycoplasma (Lonza). Cell Line Genetics performed Ba/F3 cells were grown in suspension and incubated for 90 positive short tandem repeat DNA fingerprinting analysis on minutes in the indicated media before lysis. MCF10A cells seeded SUM185PE (March 2011); cells were cultured for fewer than in 10-cm plates were incubated for 180 minutes in the indicated 2 months after identification. We also verified SUM185PE by growth media before in-well lysis. All cells were lysed in RIPA manual identification of unique variants in NGS data. DNA buffer supplemented with protease and phosphatase inhibitors. fingerprinting analysis was not performed on MCF10A or Ba/ Cell lysates [40 mg (SUM185PE) or 30 mg (Ba/F3 and MCF10A)] F3 cells, but the Ba/F3 cell line displayed the previously were separated on polyacrylamide gels and transferred to poly- published IL3 dependence phenotype (17). vinyl difluoride membranes (Millipore). Immunoblotting was performed using FGFR3 B-9 (1:200, Santa Cruz), GAPDH FGFR3/TACC3 siRNA transfection MAB374 (1:1000, Millipore), MERTK D21F11 (1:1000, Cell SUM185PE cells (8,000 cells/well) were reverse transfected Signaling Technology), phospho-Akt Ser473 D9E (1:2000, Cell in a 96-well format with RNAiMax (0.1 mL, Life Technologies) Signaling Technology),
Load more

Recommended publications
  • Transcriptomic Analysis of Pluripotent Stem Cells: Insights Into Health and Disease Jia-Chi Yeo1,2 and Huck-Hui Ng1,2,3,4,5,*
    Yeo and Ng Genome Medicine 2011, 3:68 http://genomemedicine.com/content/3/10/68 REVIEW Transcriptomic analysis of pluripotent stem cells: insights into health and disease Jia-Chi Yeo1,2 and Huck-Hui Ng1,2,3,4,5,* Abstract types, termed ‘pluripotency’, allows researchers to study early mammalian development in an artificial setting and Embryonic stem cells (ESCs) and induced pluripotent offers opportunities for regenerative medicine, whereby stem cells (iPSCs) hold tremendous clinical potential ESCs could generate clinically relevant cell types for because of their ability to self-renew, and to tissue repair. However, this same malleability of ESCs dierentiate into all cell types of the body. This unique also renders it a challenge to obtain in vitro differentiation capacity of ESCs and iPSCs to form all cell lineages of ESCs to specific cell types at high efficacy. erefore, is termed pluripotency. While ESCs and iPSCs are harnessing the full potential of ESCs requires an in-depth pluripotent and remarkably similar in appearance, understanding of the factors and mechanisms regulating whether iPSCs truly resemble ESCs at the molecular ESC pluripotency and cell lineage decisions. level is still being debated. Further research is therefore Early studies on ESCs led to the discovery of the core needed to resolve this issue before iPSCs may be safely pluripotency factors Oct4, Sox2 and Nanog [1], and, applied in humans for cell therapy or regenerative increasingly, the use of genome-level screening assays has medicine. Nevertheless, the use of iPSCs as an in vitro revealed new insights by uncovering additional trans- human genetic disease model has been useful in cription factors, transcriptional cofactors and chromatin studying the molecular pathology of complex genetic remodeling complexes involved in the maintenance of diseases, as well as facilitating genetic or drug screens.
    [Show full text]
  • LY2801653 Is an Orally Bioavailable Multi-Kinase Inhibitor with Potent
    Invest New Drugs (2013) 31:833–844 DOI 10.1007/s10637-012-9912-9 PRECLINICAL STUDIES LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models S. Betty Yan & Victoria L. Peek & Rose Ajamie & Sean G. Buchanan & Jeremy R. Graff & Steven A. Heidler & Yu-Hua Hui & Karen L. Huss & Bruce W. Konicek & Jason R. Manro & Chuan Shih & Julie A. Stewart & Trent R. Stewart & Stephanie L. Stout & Mark T. Uhlik & Suzane L. Um & Yong Wang & Wenjuan Wu & Lei Yan & Wei J. Yang & Boyu Zhong & Richard A. Walgren Received: 19 October 2012 /Accepted: 3 December 2012 /Published online: 29 December 2012 # The Author(s) 2012. This article is published with open access at Springerlink.com Summary The HGF/MET signaling pathway regulates a of a potent, orally bioavailable, small-molecule inhibitor wide variety of normal cellular functions that can be subverted LY2801653 targeting MET kinase. LY2801653 is a type-II to support neoplasia, including cell proliferation, survival, ATP competitive, slow-off inhibitor of MET tyrosine kinase apoptosis, scattering and motility, invasion, and angiogenesis. with a dissociation constant (Ki) of 2 nM, a pharmacodynamic −1 MET over-expression (with or without gene amplification), residence time (Koff) of 0.00132 min and t1/2 of 525 min. aberrant autocrine or paracrine ligand production, and mis- LY2801653 demonstrated in vitro effects on MET pathway- sense MET mutations are mechanisms that lead to activation dependent cell scattering and cell proliferation; in vivo anti- of the MET pathway in tumors and are associated with poor tumor effects in MET amplified (MKN45), MET autocrine prognostic outcome.
    [Show full text]
  • Cellular and Molecular Signatures in the Disease Tissue of Early
    Cellular and Molecular Signatures in the Disease Tissue of Early Rheumatoid Arthritis Stratify Clinical Response to csDMARD-Therapy and Predict Radiographic Progression Frances Humby1,* Myles Lewis1,* Nandhini Ramamoorthi2, Jason Hackney3, Michael Barnes1, Michele Bombardieri1, Francesca Setiadi2, Stephen Kelly1, Fabiola Bene1, Maria di Cicco1, Sudeh Riahi1, Vidalba Rocher-Ros1, Nora Ng1, Ilias Lazorou1, Rebecca E. Hands1, Desiree van der Heijde4, Robert Landewé5, Annette van der Helm-van Mil4, Alberto Cauli6, Iain B. McInnes7, Christopher D. Buckley8, Ernest Choy9, Peter Taylor10, Michael J. Townsend2 & Costantino Pitzalis1 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Departments of 2Biomarker Discovery OMNI, 3Bioinformatics and Computational Biology, Genentech Research and Early Development, South San Francisco, California 94080 USA 4Department of Rheumatology, Leiden University Medical Center, The Netherlands 5Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands 6Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Cagliari, Italy 7Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK 8Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham B15 2WB, UK 9Institute of
    [Show full text]
  • Supplemental Information
    Supplemental information Dissection of the genomic structure of the miR-183/96/182 gene. Previously, we showed that the miR-183/96/182 cluster is an intergenic miRNA cluster, located in a ~60-kb interval between the genes encoding nuclear respiratory factor-1 (Nrf1) and ubiquitin-conjugating enzyme E2H (Ube2h) on mouse chr6qA3.3 (1). To start to uncover the genomic structure of the miR- 183/96/182 gene, we first studied genomic features around miR-183/96/182 in the UCSC genome browser (http://genome.UCSC.edu/), and identified two CpG islands 3.4-6.5 kb 5’ of pre-miR-183, the most 5’ miRNA of the cluster (Fig. 1A; Fig. S1 and Seq. S1). A cDNA clone, AK044220, located at 3.2-4.6 kb 5’ to pre-miR-183, encompasses the second CpG island (Fig. 1A; Fig. S1). We hypothesized that this cDNA clone was derived from 5’ exon(s) of the primary transcript of the miR-183/96/182 gene, as CpG islands are often associated with promoters (2). Supporting this hypothesis, multiple expressed sequences detected by gene-trap clones, including clone D016D06 (3, 4), were co-localized with the cDNA clone AK044220 (Fig. 1A; Fig. S1). Clone D016D06, deposited by the German GeneTrap Consortium (GGTC) (http://tikus.gsf.de) (3, 4), was derived from insertion of a retroviral construct, rFlpROSAβgeo in 129S2 ES cells (Fig. 1A and C). The rFlpROSAβgeo construct carries a promoterless reporter gene, the β−geo cassette - an in-frame fusion of the β-galactosidase and neomycin resistance (Neor) gene (5), with a splicing acceptor (SA) immediately upstream, and a polyA signal downstream of the β−geo cassette (Fig.
    [Show full text]
  • Effects of Downregulating GLIS1 Transcript On
    Journal of Reproduction and Development, Vol. 61, No 5, 2015 —Original Article— Effects of downregulating GLIS1 transcript on preimplantation development and gene expression of bovine embryos Kazuki TAKAHASHI1), Nobuyuki SAKURAI2), Natsuko EMURA1), Tsutomu HASHIZUME1, 2) and Ken SAWAI1, 2) 1)Faculty of Agriculture, Iwate University, Iwate 020-8550, Japan 2)The United Graduate School of Agricultural Sciences, Iwate University, Iwate 020-8550, Japan Abstract. Krüppel-like protein Gli-similar 1 (GLIS1) is known as a direct reprogramming factor for the generation of induced pluripotent stem cells. The objective of this study was to investigate the role of GLIS1 in the preimplantation development of bovine embryos. GLIS1 transcripts in in vitro-matured oocytes and 1-cell to 4-cell stage embryos were detected, but they were either absent or at trace levels at the 8-cell to blastocyst stages. We attempted GLIS1 downregulation of bovine early embryos by RNA interference and evaluated developmental competency and gene transcripts, which are involved in zygotic gene activation (ZGA) in GLIS1-downregulated embryos. Injection of specific siRNA resulted in a distinct decrease inGLIS1 transcript in bovine embryos at the 4-cell stage. Although the bovine embryos injected with GLIS1-siRNA could develop to the 16-cell stage, these embryos had difficulty in developing beyond the 32-cell stage. Gene transcripts of PDHA1 and HSPA8, which are transcribed after ZGA, showed lower level in GLIS1 downregulated embryos. It is possible that GLIS1- downregulated embryos fail to initiate ZGA. Our results indicated that GLIS1 is an important factor for the preimplantation development of bovine embryos. Key words: Bovine embryo, Early development, Gene expression, GLIS1, RNA interference (J.
    [Show full text]
  • Crystal Structure of the Kinase Domain of Mertk in Complex with AZD7762 Provides Clues for Structure-Based Drug Development
    International Journal of Molecular Sciences Article Crystal Structure of the Kinase Domain of MerTK in Complex with AZD7762 Provides Clues for Structure-Based Drug Development Tae Hyun Park 1,2 , Seung-Hyun Bae 1,3 , Seoung Min Bong 1, Seong Eon Ryu 2, Hyonchol Jang 1,3 and Byung Il Lee 1,3,* 1 Research Institute, National Cancer Center, Goyang, 10408 Gyeonggi, Korea; [email protected] (T.H.P.); [email protected] (S.-H.B.); [email protected] (S.M.B.); [email protected] (H.J.) 2 Department of Bioengineering, Hanyang University, 04763 Seoul, Korea; [email protected] 3 Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, Goyang, 10408 Gyeonggi, Korea * Correspondence: [email protected]; Tel.: +82-31-920-2223; Fax: +82-31-920-2006 Received: 29 August 2020; Accepted: 21 October 2020; Published: 23 October 2020 Abstract: Aberrant tyrosine-protein kinase Mer (MerTK) expression triggers prosurvival signaling and contributes to cell survival, invasive motility, and chemoresistance in many kinds of cancers. In addition, recent reports suggested that MerTK could be a primary target for abnormal platelet aggregation. Consequently, MerTK inhibitors may promote cancer cell death, sensitize cells to chemotherapy, and act as new antiplatelet agents. We screened an inhouse chemical library to discover novel small-molecule MerTK inhibitors, and identified AZD7762, which is known as a checkpoint-kinase (Chk) inhibitor. The inhibition of MerTK by AZD7762 was validated using an in vitro homogeneous time-resolved fluorescence (HTRF) assay and through monitoring the decrease in phosphorylated MerTK in two lung cancer cell lines.
    [Show full text]
  • MERTK Antibody Catalog Number: MKT-101AP Lot Number: General Information
    FabGennix International, Inc. 9191 Kyser Way Bldg. 4 Suite 402 Frisco, TX 75033 Tel: (214)-387-8105, 1-800-786-1236 Fax: (214)-387-8105 Email: [email protected] Web: www.FabGennix.com Rabbit Polyclonal Anti-MERTK antibody Catalog Number: MKT-101AP Lot Number: General Information Product MERTK Antibody Description Affinity Purified Human cellular proto-oncogene (c- mer) mRNA Antibody C-epitope Accession # Uniprot: Q12866 GenBank: U08023.1 Verified Applications CM, ELISA, ICC, IF, IHC, IP, WB Species Cross Reactivity Human, Mouse, Rat Host Rabbit Immunogen Synthetic peptide taken within amino acid region 900-994 on MerTK protein. Alternative Nomenclature c mer proto oncogene tyrosine kinase antibody, cMER antibody, Eyk antibody, MER antibody, MER receptor tyrosine kinase antibody, MERK antibody, MERPEN antibody, Mertk antibody, MERTK c-mer proto-oncogene tyrosine kinase antibody, MGC133349 antibody, nmf12 antibody, Nyk antibody, Proto oncogene tyrosine protein kinase MER antibody, Receptor tyrosine kinase MerTK antibody, RP38 antibody, STK kinase antibody, Tyrosine-protein kinase Mer antibody Physical Properties Quantity 100 µg Volume 200 µl Form Affinity Purified Immunoglobulins Determinant C-epitope Immunoglobulin & Concentration 0.75 mg/ml IgG in antibody stabilization buffer Storage Store at -20⁰C for long term storage. Related Products Catalog # BIOTIN-Conjugated MKT100-BIOTIN FITC-Conjugated MKT100-FITC Antigenic Blocking Peptide P-MKT100 Western Blot Positive Control PC-MKT Tel: (214)-387-8105, 1-800-786-1236 Fax: (214)-387-8105 Email: [email protected] Web: www.FabGennix.com Recommended Dilutions DOT Blot 1:10,000 ELISA 1:10,000 Immunocytochemistry 1:200 Immunofluorescence 1:200 Immunohistochemistry 1:200 Immunoprecipitation 1:200 Western Blot 1:750 Application Verification: WB using MKT-101AP and human RPE cells.
    [Show full text]
  • Isolation and Characterization of a Novel Gene CLUAP1 Whose Expression Is Frequently Upregulated in Colon Cancer
    Oncogene (2004) 23, 9289–9294 & 2004 Nature Publishing Group All rights reserved 0950-9232/04 $30.00 www.nature.com/onc SHORT REPORT Isolation and characterization of a novel gene CLUAP1 whose expression is frequently upregulated in colon cancer Meiko Takahashi1, Yu-Min Lin2, Yusuke Nakamura1 and Yoichi Furukawa*,1 1Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai Minato-ku, Tokyo 108-8639, Japan; 2Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital, 95 Wen Chang Road, Taipei 11160, Taiwan To disclose mechanisms of colorectal carcinogenesis and appear to be upregulated frequently in the cancer tissues identify novel diagnostic markers and drug targets for compared with the corresponding noncancerous cells. treatment of these tumors, we previously analysed the Since carcinogenesis involves activation of oncogenes expression profiles of 11 colorectal cancers using a and/or inactivation of tumor suppressor genes, en- genome-wide cDNA microarray containing 23 040 genes. hanced expression of at least some of these upregulated Among the genes commonly transactivated in the cancers, genes may reflect oncogenic properties. we identified a novel human gene, which we termed Among the genes with frequently elevated expression CLUAP1 (clusterin-associated protein 1). It encodes a in cancer tissues in our microarray data, an EST with an nuclear protein of 413 amino acids containing a coiled-coil in-house accession number of B9223 corresponding to domain. To investigate its function, we searched for KIAA0643, Hs. 155995 in UniGene cluster (http:// CLUAP1-interacting proteins using yeast two-hybrid www.ncbi.nlm.nih.gov/UniGene/), was upregulated in system and identified nuclear Clusterin.
    [Show full text]
  • The Ciliopathy-Associated CPLANE Proteins Direct Basal Body Recruitment of Intraflagellar Transport Machinery
    The ciliopathy-associated CPLANE proteins direct basal body recruitment of intraflagellar transport machinery The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Toriyama, M., C. Lee, S. P. Taylor, I. Duran, D. H. Cohn, A. Bruel, J. M. Tabler, et al. 2016. “The ciliopathy-associated CPLANE proteins direct basal body recruitment of intraflagellar transport machinery.” Nature genetics 48 (6): 648-656. doi:10.1038/ng.3558. http:// dx.doi.org/10.1038/ng.3558. Published Version doi:10.1038/ng.3558 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:29626113 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Nat Genet Manuscript Author . Author manuscript; Manuscript Author available in PMC 2016 November 09. Published in final edited form as: Nat Genet. 2016 June ; 48(6): 648–656. doi:10.1038/ng.3558. The ciliopathy-associated CPLANE proteins direct basal body recruitment of intraflagellar transport machinery Michinori Toriyama1, Chanjae Lee1, S. Paige Taylor2, Ivan Duran2, Daniel H. Cohn3, Ange- Line Bruel4, Jacqueline M. Tabler1, Kevin Drew1, Marcus R. Kelley5, Sukyoung Kim1, Tae Joo Park1,**, Daniella Braun6, Ghislaine Pierquin7, Armand Biver8, Kerstin Wagner9, Anne Malfroot10, Inusha Panigrahi11, Brunella Franco12,13, Hadeel Adel Al-lami14, Yvonne Yeung14, Yeon Ja Choi15, University of Washington Center for Mendelian Genomics16, Yannis Duffourd4, Laurence Faivre4,17, Jean-Baptiste Rivière4,18, Jiang Chen15, Karen J.
    [Show full text]
  • Identification Des Bases Moléculaires Et Physiopathologiques Des Syndromes Oro-Facio-Digitaux Ange-Line Bruel
    Identification des bases moléculaires et physiopathologiques des syndromes oro-facio-digitaux Ange-Line Bruel To cite this version: Ange-Line Bruel. Identification des bases moléculaires et physiopathologiques des syndromes oro-facio- digitaux. Génétique. Université de Bourgogne, 2016. Français. NNT : 2016DIJOS043. tel-01635713 HAL Id: tel-01635713 https://tel.archives-ouvertes.fr/tel-01635713 Submitted on 15 Nov 2017 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. UNIVERSITE DE BOURGOGNE UFR des Sciences de Santé THÈSE Pour obtenir le grade de Docteur de l’Université de Bourgogne Discipline : Sciences de la vie par Ange-Line Bruel 21 Septembre 2016 Identification des bases moléculaires et physiopathologiques des syndromes oro-facio-digitaux Directeur de thèse Pr Christel Thauvin-Robinet Co-directeur de thèse Dr Laurence Jego Dr Jean-Baptiste Rivière Jury Pr Faivre Laurence, Président Pr Thauvin-Robinet Christel, Directeur de thèse Dr Saunier Sophie, Rapporteur Pr Geneviève David, Rapporteur Pr Attié-Bittach Tania, Examinateur 1 A ma famille 2 Remerciements Je voudrais remercier en premier lieu Laurence Faivre, de m’avoir accueillie au sein du laboratoire Génétique des Anomalies du Développement, pour l’intérêt porté à mes travaux et pour son soutien.
    [Show full text]
  • Rabbit Anti-CLUAP1/FITC Conjugated Antibody-SL6805R-FITC
    SunLong Biotech Co.,LTD Tel: 0086-571- 56623320 Fax:0086-571- 56623318 E-mail:[email protected] www.sunlongbiotech.com Rabbit Anti-CLUAP1/FITC Conjugated antibody SL6805R-FITC Product Name: Anti-CLUAP1/FITC Chinese Name: FITC标记的成簇相关蛋白1抗体 Alias: Clusterin associated protein 1; FLJ13297; KIAA0643; CLUA1_HUMAN. Organism Species: Rabbit Clonality: Polyclonal React Species: Human,Mouse,Rat,Chicken,Dog,Pig,Horse,Rabbit,Sheep, IF=1:50-200 Applications: not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. Molecular weight: 48kDa Form: Lyophilized or Liquid Concentration: 1mg/ml immunogen: KLH conjugated synthetic peptide derived from human CLUAP1 Lsotype: IgG Purification: affinity purified by Protein A Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibodywww.sunlongbiotech.com is stable at room temperature for at least one month and for greater than a year Storage: when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. background: CLUAP1 (Clusterin associated protein 1) is a 413 amino acid nuclear protein that exists as two alternatively spliced isoforms that interact with Clusterin. CLUAP1 is suggested to play a role in apoptosis and cell proliferation, and is expressed in testis, thrachea and thyroid, with low levels found in adrenal gland and spinal cord. The gene encoding Product Detail: CLUAP1 maps to human chromosome 16, which encodes over 900 genes and comprises nearly 3% of the human genome.
    [Show full text]
  • A High Throughput, Functional Screen of Human Body Mass Index GWAS Loci Using Tissue-Specific Rnai Drosophila Melanogaster Crosses Thomas J
    Washington University School of Medicine Digital Commons@Becker Open Access Publications 2018 A high throughput, functional screen of human Body Mass Index GWAS loci using tissue-specific RNAi Drosophila melanogaster crosses Thomas J. Baranski Washington University School of Medicine in St. Louis Aldi T. Kraja Washington University School of Medicine in St. Louis Jill L. Fink Washington University School of Medicine in St. Louis Mary Feitosa Washington University School of Medicine in St. Louis Petra A. Lenzini Washington University School of Medicine in St. Louis See next page for additional authors Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs Recommended Citation Baranski, Thomas J.; Kraja, Aldi T.; Fink, Jill L.; Feitosa, Mary; Lenzini, Petra A.; Borecki, Ingrid B.; Liu, Ching-Ti; Cupples, L. Adrienne; North, Kari E.; and Province, Michael A., ,"A high throughput, functional screen of human Body Mass Index GWAS loci using tissue-specific RNAi Drosophila melanogaster crosses." PLoS Genetics.14,4. e1007222. (2018). https://digitalcommons.wustl.edu/open_access_pubs/6820 This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact [email protected]. Authors Thomas J. Baranski, Aldi T. Kraja, Jill L. Fink, Mary Feitosa, Petra A. Lenzini, Ingrid B. Borecki, Ching-Ti Liu, L. Adrienne Cupples, Kari E. North, and Michael A. Province This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/open_access_pubs/6820 RESEARCH ARTICLE A high throughput, functional screen of human Body Mass Index GWAS loci using tissue-specific RNAi Drosophila melanogaster crosses Thomas J.
    [Show full text]